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There is increasing importance placed upon noninvasive assessment of gut inﬂammation. These tools are likely to be the key in
diﬀerentiating intestinal inﬂammatory disease from functional disorders and in monitoring the response to intervention in
individuals with known inﬂammatory conditions. Although various noninvasive markers are currently available, they have
limitations and do not provide ideal utility. This review focuses on emerging markers of gut inﬂammation, highlighting the
potential of speciﬁc markers.
1. Introduction
Historically, noninvasive assessments of gut inﬂammation
have utilized tests such as the detection of fecal white blood
cells [1] and whole stool lavage. However, these provide
inadequate assessment of gut inﬂammation. The need to
improve assessment of gut inﬂammation has driven investi-
gation into additional biomarkers of inﬂammation. Calpro-
tectin, S100A12, and lactoferrin have generally been well
described as fecal biomarkers in inﬂammatory bowel disease
(IBD) [2]. However, other less well-established fecal bio-
markers include M2-pyruvate kinase, osteoprotegerin,
myeloperoxidase, HMGB1, chitinase 3-like 1, defensins,
matrix metalloproteinases, and human nucleic acid: most of
these have been assessed in single cohorts and require further
extensive evaluations and validation. This review will focus
on these novel fecal biomarkers, with mention of the future
potential of biomarkers in diagnosis, prognosis, and moni-
toring of disease activity in IBD.
2. M2-PK
Pyruvate kinase, a key enzyme in the glycolytic pathway [3],
can be present in skeletal muscle, heart or brain as a tetramer
(M1), or in undiﬀerentiated and proliferating tissues as a
dimer (termed M2-PK) [4, 5]. M2-PK can be measured in
serum or stool and is stable in stool for up to two days [6].
Fecal M2-PK concentrations are increased in colorectal
carcinoma [7], but also in gut inﬂammation [3] reﬂecting
increased cell turnover. Although, it is postulated that
intestinal epithelial cells may be protected against apoptosis
by the upregulation of M2-PK through the Bcl-xl pathway
in Crohn’s disease (CD) [8].
High levels of M2-PK were documented in 81 adults
diagnosed with IBD [3] (Table 1). This cohort was compared
to a group of 43 subjects with irritable bowel syndrome (IBS)
and 7 with colorectal carcinoma. M2-PK concentrations were
higher in patients with ulcerative colitis (UC) or CD than in
the controls. Furthermore, higher levels were evident in indi-
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viduals with active IBD than in those with quiescent disease.
In a further study, M2-PK was assessed in 105 adults present-
ing with undiﬀerentiated gastrointestinal symptoms and 94
healthy controls [9]. The 14 adults subsequently diagnosed
with organic diseases (only 10 with IBD) had higher fecal
concentrations of M2-PK than those with functional symp-
toms or the controls. M2-PK measurement provided sensi-
tivity of 67% and speciﬁcity of 88% in distinguishing
between organic and functional diagnoses.
Fecal M2-PK was assessed in a group of Polish children
with IBD [4]. Seventy-ﬁve children with UC, 32 with CD,
and 35 healthy control children provided stool samples.
M2-PK levels were higher in children with IBD, and levels
correlated with pediatric Crohn disease activity index
(PCDAI [10, 11]) scores in the 32 children with CD.
Although mean M2-PK levels were higher in those with
active disease, 47% of the children with IBD judged to be in
remission also had elevated M2-PK (Table 2(a)).
In a recent Australian study, mean fecal M2-PK levels
were also higher in 17 children with active CD than in 21
healthy controls (p = 0 0007) [12]. However, M2-PK levels
did not correlate with PCDAI scores or serum inﬂammatory
markers. There was no relationship between fecal M2-PK
and fecal S100A12 levels in the children with active CD.
The children with ileocolonic disease tended to have higher
M2-PK concentrations than those with isolated colonic or
ileal disease (Table 2(b)).
High fecal M2-PK levels also were demonstrated in
children with active UC [13]. M2-PK and three other fecal
markers (calprotectin, S100A12, and lactoferrin) were evalu-
ated as indicators of the response to ﬁrst line medical therapy
in 101 children with acute severe UC.M2-PK was found to be
superior to the other markers in identifying those who subse-
quently failed intravenous corticosteroids.
In 2014, Czub et al. [14] directly compared M2-PK and
calprotectin in assessing the severity and activity of paediatric
Table 1: Use of novel fecal markers as diagnostic test for IBD.
Ref Age Population N Comparison groups Cut-oﬀ Sn Sp PPV NPV p value
M2 pyruvate kinase (M2-PK)
[3] P HC/CD/UC 142
HC versus IBD 4U/g 96.2 94.3 96.2 94.3
NA
HC versus CD 4U/g 100 94.3 89.5 100
HC versus UC 4U/g 94.3 94.3 94.3 94.3
HC versus IBD 5U/g 94.2 94.3 96.1 91.7
HC versus CD 5U/g 94.1 97.1 88.9 97.1
HC versus UC 5U/g 94.3 97.1 97.1 94.4
[10] P HC/CD 38 HC versus CD 0.0007
Osteoprotegerin (OPG)
[29] P HC/CD 127 HC versus CD <0.0001
Myeloperoxidase (MPO)
[34] A HC/UC 74 HC versus UC 0.065U/ml 89 51 89 51 NA
[36] A HC/UC 109 HC versus UC 0.065U/ml <0.001
[38] A HC/CD/UC 51
HC versus CD <0.0001
HC versus UC <0.0001
High-mobility group box (HMGB1)
[39] P HC/CD/UC 54
HC versus CD <0.001
HC versus UC <0.001
Chitinase 3-like 1 (CHI3L1)
[46] P HC/CD/UC 237
HC versus IBD 13.7 ng⁄g 84.7 88.9 96.8 59.3
HC versus CD 81.6 80 93.9 53.3
HC versus UC 88.2 100 100 66.7
Human β defensin (HBD) 2
[49] P HC/CD/IC/UC 46
HC versus IBD 0.0002
HC versus CD <0.01
HC versus IC <0.01
HC versus UC <0.0001
CD versus UC 0.0063
[50] A HC/IBS/UC 100
HC versus IBS 0.032
HC versus UC <0.001
IBS versus UC 0.165
Age: A: adult; P: paediatric; N: number of patients; Sn: sensitivity; Sp: speciﬁcity; PPV: positive predictive value; NPV: negative predictive value; HC: healthy
controls; IBD = CD+UC(+IC); CD: Crohn’s disease; UC: ulcerative colitis; IC: inﬂammatory colitis; NA: not available.
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IBD. Truelove-Witts score was used to describe disease sever-
ity in UC patients, and PCDAI was used to assess CD
patients. The performance of M2-PK was described as infe-
rior to calprotectin to identify IBD, UC, and CD from healthy
controls. In addition, M2-PK was inferior to calprotectin in
identifying UC and CD in remission amongst healthy con-
trols. It was postulated that calprotectin reﬂects paediatric
IBD severity and activity better than M2-PK. However, this
is in contradiction of the observation of Roszak et al. [15]
who state that M2-PK is a more sensitive marker than
Table 2: (a) Use of novel fecal markers to assess disease activity (inactive versus active) in IBD. (b) Correlation of novel fecal markers to assess
severity in IBD.
(a)
Ref Age Pop. N Inactive Active p value Comments
M2 pyruvate kinase (M2-PK)
[3] A
CD 31 [5] 0.55U/ml [26] 30U/ml <0.005
UC 50 [13] 1.2U/ml [37] 40U/ml 0.006
[4] P
CD 32 [15] 16.5U/g [17] 96.3U/g NS
UC 75 [40] 1.5U/g [35] 149U/g 0.0003
Myeloperoxidase (MPO)
[38] A
CD 32 [15] [18] <0.001 Active: IOIBD score ≥ 2
UC 33 [14] [18] <0.001 Truelove and Witts’ severity index
High-mobility group box (HMGB1)
[39] P
CD 19 [8] [11] NS Active: PCDAI > 10
UC 21 [8] [13] NS Active: PUCAI ≥ 10
Chitinase 3-like 1 (CHI3L1)
[46] P
CD 87 [39] 18.4 ng/g [48] 632.7 ng/g <0.01 Active: PCDAI ≥ 10
UC 94 [50] 15.8 ng/g [44] 366.6 ng/g <0.01 Active: PUCAI ≥ 10
Human nucleic acid
[72] A UC 54 3.9 copies/μg 259.0 copies/μg <0.01 Active: colitis activity index ≥ 7
(b)
Ref Age Pop. N r p value Disease severity
M2 pyruvate kinase (M2-PK)
[12] P CD 17 NA NS PCDAI
[15] P
CD 47 0.82 <0.05 PCDAI
UC 37 0.77 <0.05 Truelove and Witts’ severity index
Osteoprotegerin (OPG)
[27] P CD 82
0.15 0.31 PCDAI
0.16 0.21 Modiﬁed PCDAI
0.10 0.22 PCDAI with logged OPG
0.35 0.0001 Modiﬁed PCDAI with logged OPG
Myeloperoxidase (MPO)
[36] A UC 55
NA 0.02 Endoscopy severity
NA NS Endoscopic extent or histology score
Chitinase 3-like 1 (CHI3L1)
[46] P
CD 25
0.61 <0.01 SES-CD scoring system
0.49 <0.01 PCDAI
UC 42
0.73 <0.01 Sum of the Matts’ score
0.47 <0.01 PUCAI
Human nucleic acid
[71] A UC 31
0.59 <0.05 Clinical index of Rachmilewitz
0.76 <0.01 Endoscopic score
Age: A: adult; P: paediatric, values are median; Pop.: type of population; N: number of patients; NS: nonsigniﬁcant; square brackets []: number of patients,
r: correlation coeﬃcient; CD: Crohn’s disease; UC: ulcerative colitis; IOIBD: International Organization for the Study of Inﬂammatory Bowel Diseases score;
PCDAI: paediatric Crohn’s disease activity index; PUCAI: paediatric ulcerative colitis activity index; SES-CD: simple endoscopic score for Crohn’s disease.
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calprotectin and lactoferrin in evaluating disease activity in
UC or CD (Table 2(b)). Further studies are required in this
area to clarify this discrepancy.
3. Osteoprotegerin
Osteoprotegerin, also known as osteoprotegrin, (OPG) is a
basic glycoprotein that is found either as a 60 kDa monomer
or as a 120 kDa dimer. OPG is a cytokine receptor and
belongs to the TNF superfamily [16, 17]. OPG can be pro-
duced by a wide range of cell types, including osteoblasts, B
lymphocytes, dendritic cells, bone marrow stromal cells, epi-
thelial cells, and monocytes/macrophages [17, 18]. OPG
production may be regulated by proinﬂammatory mediators
[16, 19, 20]. The cellular sources of OPG are distinct to
those of the established inﬂammatory markers calprotectin,
lactoferrin, and S100A12.
OPG has a well-established role in bone turnover. The
equilibrium of osteoclast and osteoblast activity is coordi-
nated primarily by the receptor activator of nuclear factor-
κB (RANK) and its ligand (RANKL). OPG acts as a decoy
receptor for RANK [16, 18, 20–22]. In this role as a decoy
receptor, OPG inhibits the diﬀerentiation, survival, and func-
tion of osteoclasts by competitively blocking the interaction
between RANK and RANKL [18] promoting bone formation
as a counter regulatory response to factors such as inﬂamma-
tory cytokines (IL-1, TNFα) [23]. This is of importance in
IBD where there is an established increased fracture risk
associated with the disease [24]. However, the impact of
intestinal-derived OPG upon bone loss in the context of
IBD is yet to be directly established [25].
OPG also may have a role in IBD pathogenesis, quite sep-
arate to the role in bone metabolism. The OPG/RANKL/
RANK triad may contribute to mucosal and systemic inﬂam-
mation [17, 20, 22]. RANK, RANKL, and OPG decrease the
functional capacity of dendritic cells (DC) and activated T
cells but enhance B cell maturation [26–28].
Recently, a small number of studies have demonstrated
that OPG can be a useful marker of inﬂammation in the con-
text of IBD. Nahidi et al. [27] evaluated OPG in children with
CD and control children without evidence of underlying gut
disease (Table 1, Table 2(b)). OPG was detected in serum,
mucosal biopsies, and in the stool. Levels of OPG were
greatly increased in stool samples collected from the children
with CD and in the endoscopically obtained mucosal biop-
sies. In addition, serum levels of OPG were markedly elevated
in those children with severe CD compared to control values.
Furthermore, serum and fecal levels fell substantially with
remission induction therapy in a subset of children (exclusive
enteral nutrition in this instance). In this group of children
with CD, those children with isolated colonic involvement
had greater levels than a group with ileocolonic disease and
serum and fecal OPG did not correlate. Although OPG did
not correlate with the PCDAI scores, levels did correlate with
modiﬁed PCDAI scores (includes the serum inﬂammatory
marker components of the PCDAI, with the addition of a
score for CRP [29]). In addition, fecal OPG also correlated
with fecal S100A12 and serum CRP at diagnosis of IBD, yet
did not correlate following treatment.
Galliera et al. [30] measured serum OPG and RANKL
levels following the administration of the anti-TNF-α inhib-
itor inﬂiximab in adult patients with IBD. In this study, OPG
levels also decreased with treatment, in correlation with fall-
ing CRP levels. It is important to note that OPG levels did not
fall acutely and were only signiﬁcantly lower 22 weeks after
the commencement of therapy. The authors suggest that in
this setting, OPG is representative of the inﬂammatory
response and not bone turnover.
In addition, Sylvester et al. [31] recently investigated
whether fecal OPG was able to act as a predictive marker
for the treatment of UC in a large group of children. They
reported that fecal OPG was elevated in patients who had
failed ﬁrst-line corticosteroid therapy and required inﬂixi-
mab or colectomy. Further, OPG was superior in predicting
response to therapy compared to lactoferrin or S100A12.
These reports indicate that OPGmay be useful in monitoring
the inﬂammatory response in IBD. However, the authors
note that OPG is rapidly degraded in stool at room tempera-
ture and, therefore, optimal stool collection and storage con-
ditions must be used to accurately assess fecal OPG.
There are, however, conﬂicting reports on fecal OPG
expression. In a preliminary investigation, Skinner et al.
[32] report that fecal OPG is elevated at diagnosis of UC
but not of CD and, therefore, may have potential as a UC spe-
ciﬁc marker. This is in contrast to Nahidi et al. [27] who
report that OPG is elevated at diagnosis of CD, albeit levels
were more elevated with severe disease. Nevertheless, the
expression pattern of OPG appears unique amongst the stool
inﬂammatory markers investigated to date. Consequently,
OPG has the potential to enhance knowledge of the intestinal
inﬂammatory picture. However, it is clear that further inves-
tigation into the settings of OPG expression in the intestinal
mucosa is required to advance our understanding of how
OPG ﬁts into the inﬂammatory cascade and its role in the
pathogenesis of the inﬂammatory response in IBD.
4. Myeloperoxidase
Myeloperoxidase (MPO) is one of a number of proteins
stored in and released from neutrophil secretory granules: it
is stable for at least 3 days in stool [33]. One potential limita-
tion of myeloperoxidase as an inﬂammatory marker is its cat-
ionic charge, which may lead it to bind to fecal particles,
limiting reliability as a disease marker [34].
MPO levels were greatly increased in a cohort of 55
Indian patients with UC compared to 74 healthy controls
(0.42 units versuss 0.06 units: p < 0 001) [35] (Table 1). In
diﬀerentiating between UC and no inﬂammation, a sensitiv-
ity of 89% but speciﬁcity of just 51.4% was observed. Levels
correlated with endoscopic severity scores and fell following
therapeutic intervention. However, levels did not correlate
with endoscopic extent or histological severity scores [36]
(Table 2(b)).
Sangfelt et al. [37] also showed signiﬁcant correlation
between MPO concentrations and endoscopic and clinical
activity in a study of 11 Swedish patients with UC. A Japanese
study involving 33 patients with UC and 32 patients with CD
again illustrated a strong relationship between MPO and
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endoscopic extent or histological grade [38] (Table 2(a)). In
this instance, MPO levels fell in response to therapy and as
suggested earlier fecal MPO may be used as a noninvasive
biomarker for the response to treatment [36].
5. HMGB1
The nuclear protein, high-mobility group box (HMGB) 1, is
released from immune cells in the setting of inﬂammation.
It has been described as an alarmin, with key inﬂammatory
properties.
One study has assessed HMGB1 in a cohort of children
with IBD [39]. Fecal levels of HMGB1 protein were greatly
increased in 40 children with IBD, whilst being undetectable
in 13 healthy controls (Table 1). These authors documented
high cytoplasmic levels of HMGB1 in mucosal biopsies, sug-
gesting this to be the source of the increased production.
Although likely derived from diﬀerent cellular sources, fecal
HMGB1 correlated with fecal calprotectin (r = 0 77). Fur-
thermore, fecal concentrations reﬂected endoscopic severity
in a subset of 16 children with clinically inactive disease but
active mucosal ﬁndings. These results were reproduced by
the same group in adult patients with IBD [39]. However,
there was no signiﬁcant correlation between HMGB1 levels
and activity indexes (Crohn’s disease activity index (CDAI)
and partial Mayo score for UC) (Table 2(a)). More interest-
ingly, there was a signiﬁcant correlation between fecal
HMGBI levels and endoscopic indices (r = 0 763, p < 0 001
for the Simple endoscopic score for Crohn’s disease (SES-
CD) and r = 0 44, p < 0 05 for endoscopic Mayo subscore).
Palone et al. [40] therefore hypothesise that fecal HMGB1
could play a role as a marker of subclinical gut inﬂammation
and a novel biomarker of mucosal healing.
HMGB1 has previously been shown to reﬂect intestinal
inﬂammation in the context of enteric infection [41]. In addi-
tion, animal studies have shown that HMGB1 production
and signalling can be signiﬁcantly modulated by therapeutic
intervention with dipotassium glycyrrhizate [42] or ethyl
pyruvate [43] suggesting that such intervention could have
a place in human IBD. Although these data could support
HMGB1 having a role in IBD, further assessments are
required before HMGB1 could be considered further.
6. Chitinase 3-Like 1
Chitinase 3-like 1 (CHI3L1) binds chitin, an abundant
polysaccharide. The expression of CHI3L1 is upregulated in
various cell types such as colonocytes and lamina propria
macrophages [44]. This protein is known to enhance bacte-
rial invasion and adhesion to epithelial cells. Increased serum
levels of this protein have been demonstrated in patients with
IBD [45].
Aomatsu et al. [46] demonstrated marked elevations of
fecal CHI3L1 in 92 children with IBD compared to healthy
controls. Using a cut-oﬀ of 13.7 ng/g, fecal concentrations
were able to distinguish between IBD and control children
with sensitivity of 84.7% and speciﬁcity of 88.9% (Table 1).
In both UC and CD, fecal levels correlated with endoscopic
severity scores and also related closely with fecal calprotectin
levels (Table 2(a),Table2(b)). Finally, in a subset of 11children
with paired samples before and after therapy to induce remis-
sion, fecal levels of CHI3L1 were noted to fall (p = 0 01). In
addition to its presumed role in IBD, CHI3L1 was suggested
by Chen et al. [47] to play a role in inﬂammation-associated
neoplastic modiﬁcation in colonic epithelial cells.
Although there is some rationale to consider that this
protein may be a useful marker, further assessment and val-
idation is required.
7. Human Beta Defensin 2
Defensins are innate antimicrobial peptides that are pro-
duced at epithelial borders and contribute to host defence
[48]. Several members of the β defensin group are produced
in the colon by epithelial cells and plasma cells. An initial
study completed in French children demonstrated that
human β defensin (HBD) 2 could be measured in stool
samples [49]. Although able to be detected in control
children, levels were substantially higher in those with IBD
(p = 0 0002), especially those with UC (Table 1).
One further study has evaluated fecal levels of HBD2 in a
group of adults [50]. HBD2 was elevated in 30 adult patients
with UC compared to 24 healthy controls (106.9 versus 29.9:
p = 0 001) (Table 1). However, levels were also increased in a
group of 46 patients with IBS compared to the control group,
but not diﬀerent to those with UC. These results suggest a
proinﬂammatory activation of the mucosal immune system
in patients with IBS as well as IBD and suggest that this
marker may not be speciﬁc to IBD.
8. Matrix Metalloproteinase
The matrix metalloproteinases (MMP) are a family of key
biological mediators involved in tissue degradation and resti-
tution. A number of studies have examined the roles of MMP
proteins in IBD [51, 52]: these include regulation, inﬂamma-
tion, and tissue destruction. Furthermore, the balance
between MMPs and their inhibitors (tissue inhibitors of
metalloproteinases: TIMPs) may inﬂuence ﬁbrosis and stric-
ture development.
MMPs are expressed in areas of inﬂammation and ulcer-
ation in the gut, and several MMPs are overexpressed in IBD
[51, 53–57]. MMP-2 has been reported to be elevated in the
inﬂamed tissue from IBD patients [58]. Gao et al. [58]
reported increased tissue mRNA levels that correlated with
severity of inﬂammation. Immunohistochemistry studies
revealed that MMP-2 was present in the extracellular matrix
of the submucosa. Furthermore, elevated serum [59] and
urine [60] levels have also been reported in IBD patents.
MMP was also monitored in patients with CD managed
with inﬂiximab. Interestingly,MMP-2 serum levels increased,
both in responders and nonresponders to treatment, and this
was hypothesised to be due to increased intestinal cell turn-
over [59]. Garg et al. [61] reported the ﬁndings of an experi-
mental colitis model using dextran sodium sulphate-
induced colitis in MMP-2-ablated mice. In this model, the
MMP-2-ablated mice developed a more severe colitis than
the control animals indicating that MMP-2 has a protective
5Mediators of Inﬂammation
role against developing colitis and may explain elevated levels
in response to treatment.
Most interest in MMPs as disease markers of IBD has
focused on MMP-9. Koﬂa-Dlubacz et al. [62] showed that
serum MMP-9 concentrations correlated with CRP levels
and with disease activity (using PCDAI scores) in 82 children
with CD [63] and in 31 children with UC. Annahazi et al.
[64] have subsequently delineated fecal levels in 47 patients
with IBD, 23 with IBS, and 24 control patients. In the subjects
with UC, MMP-9 concentrations correlated with endoscopic
and clinical severity scores (p < 0 001 for both relationships)
and were also associated with CRP levels (p = 0 002).
Furthermore, MMP-9 levels correlated with fecal calprotec-
tin (p = 0 014).
Despite MMP-9 being elevated in both CD and UC, the
performance of MMP-9 as a disease marker appears to be
better in UC and pouchitis [65]. Kolho et al. [66] compared
the performance of MMP-9 to that of calprotectin in distin-
guishing IBD from non-IBD subjects. Although MMP-9 per-
formance was comparable to calprotectin in those with UC,
MMP-9 was inferior to calprotectin in CD [66]. There are
diﬀering reports regarding the response of MMP-9 to ther-
apy. Gao et al. [59] reported that serum MMP-9 levels fell
in response to a single dose of inﬂiximab; however, Makitalo
et al. [67] reported that serumMMP-9 levels were not altered
with therapy. Overall, it appears that MMP-9 may be a useful
biomarker in the assessment of undiﬀerentiated gut symp-
toms and in the evaluation of mucosal inﬂammatory activity
although further work is needed to more fully describe these
expression patterns.
Several other MMP’s are also elevated in IBD. MMP-7
and MMP-13 mRNA levels were elevated in biopsy speci-
mens from CD and UC patients [68]. Serum MMP-3 [62]
and MMP-8 [67] levels are also elevated in IBD. However,
the role of MMP as markers in IBD may not be restricted
to reporters of inﬂammation and tissue repair. MMP expres-
sion is also associated with colorectal tumors. MMP-7
mRNA had been detected in cancerous intestinal tissue [69]
and has been proposed to be involved in the growth of
tumors [70]. Therefore, MMP-7 may also have a potential
role in colorectal cancer screening, including in the context
of colitis-associated cancer. However, fecal evaluation of this
marker is not yet described.
9. Human Nucleic Acid (DNA and miRNA)
One study has assessed human deoxyribonucleic acid levels
in stool of 36 individuals with UC [71]. Excretion of DNA
correlated with clinical disease activity and endoscopic sever-
ity (Table 2(b)). In diﬀerentiating between active disease and
remission, this test provided sensitivity of 67% and speciﬁcity
of 100%. The same group subsequently assessed this bio-
marker in a cohort of 54 adults with inactive UC [72]
(Table 2(a)). Over a 12-month period of observation, 23 of
the subjects relapsed. Fecal DNA levels remained stable in
those who remained well, whilst levels increased in the
patients with relapse, providing a predictive marker.
In addition to DNA, RNA or more speciﬁcally micro-
RNA (miRNA) has the potential to be used as a disease
marker in IBD. miRNAs are small noncoding RNA mole-
cules that are capable of regulating gene expression at the
posttranscriptional level. Expression patterns have been
described in intestinal biopsies collected from IBD patients
with a number of speciﬁc miRNA reported to be upregulated
in both CD and UC [73–75]. In CD, it has been documented
by Wu et al. [75] that the pattern of expression of miRNA in
ileal and colonic biopsies diﬀers signiﬁcantly, meaning that
no miRNA expressions were overlapping. In CD and UC,
when compared to healthy controls, speciﬁc upregulated
miRNA (CD [76], UC [77]) and downregulated miRNA
(CD [78], UC [76]) were described. Importantly, diﬀeren-
tially expressed miRNA were also detected in the serum of
IBD patients indicating the potential of these molecules to
be used as disease markers.
However, there are several diﬃculties that need to be
overcome to compare these studies. For example, concurrent
medications, the inﬂammatory status, and the location of the
biopsy need to be considered when interpreting the role of
miRNAs [79, 80]. Further investigation of the detection of
miRNA in stool is required. In addition, the full role of these
molecules in IBD is still required; however, diﬀerential
expression of speciﬁc miRNA have been implicated in disease
pathogenesis [74].
10. Future Potential of Biomarkers in IBD
A biomarker can be described as a product that provides a
measurable indication of the presence and/or severity of dis-
ease or physiological state of an organism. The holy grail of a
biomarker is that it is disease speciﬁc, correlates highly with
disease severity, and can provide both diagnostic and prog-
nostic indications. To date, several promising fecal bio-
markers for IBD have been identiﬁed. However, none of the
currently described markers are disease speciﬁc so the search
for better biomarkers of IBD continues. A number of prom-
ising novel biomarkers have been identiﬁed, and this article
has described a portion of the most promising novel markers.
However, there are many more potential biomarkers of IBD
and further work is required to determine if any of the newly
identiﬁed markers will be equal to, or surpass, the utility of
currently available markers. The aims of the tables are to
describe and compare the current knowledge in the use of
novel markers: as markers of diagnostic tests for IBD
(Table 1), as markers to assess disease activity (inactive ver-
sus active) in IBD (Table 2(a)), and ﬁnally, as markers of dis-
ease severity in IBD (Table 2(b)).
The initial identiﬁcation of calprotectin as a biomarker of
IBD was greeted with great enthusiasm and promise that it
would impact clinical care. However, after nearly 30 years
of calprotectin research, the incorporation of this biomarker
into a routine clinical care has been slow. Calprotectin has
not replaced current nonspeciﬁc inﬂammatory markers, but
when used, it is generally used as an adjunct disease marker.
Therefore, it is reasonable to suspect a long wait for new IBD
biomarkers to appear in the clinic. Nevertheless, biomarkers
of IBD have a bright future, in research studies at least, as
prognostic indicators and in the search for personalised and
improved IBD clinical care.
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11. Conclusion
There also are several promising markers described here that
likely reﬂect diﬀerent cellular sources and diﬀerent aspects of
the IBD response. Currently, no single marker appears to be
sought after highly sensitive, diagnostic, and prognostic IBD
speciﬁc indicator. However, a number of novel biomarkers
have been evaluated in just one or two cohorts: these all
require more extensive assessments in various settings to
establish their roles in identifying, monitoring, and predict-
ing disease behaviour.
More clinical studies are required to ascertain the full
potential of fecal biomarkers in IBD. Although such evalua-
tions should focus on speciﬁc biomarkers, comparative
assessments are also required, yet there remains plenty of
potential for novel biomarkers to impact clinical care.
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